No products in the cart.
CWHP Interactive Case Studies
Certified Women’s Health Pharmacist (CWHP)
The Scenario: Contraceptive Counseling with Comorbidities
A 24-year-old female patient wants to start a reliable form of birth control. She has heard about "the pill" from her friends and is interested in that option. Your role is to take a brief medical history, assess her eligibility for various contraceptive methods based on established guidelines, and help her choose a safe and effective option that aligns with her health profile.
Patient Data & Guidelines
Patient Health Profile
- Medical History: Migraine with aura, diagnosed at age 20.
- Medications: Sumatriptan as needed.
- Lifestyle: Non-smoker.
CDC MEC for Contraceptive Use (Excerpt)
Condition: Migraine with Aura
- Combined Hormonal Contraceptives: MEC Category 4 (Unacceptable risk)
- Progestin-Only Pills & IUDs: MEC Category 1 (No restriction)
Your Task
Task 1: What is the single most important factor in this patient's medical history that will guide her contraceptive options?
Answer:
Her history of migraine with aura is the most critical factor, as it carries a specific and strong contraindication to certain types of hormonal contraception.
Task 2: Based on the CDC MEC guidelines, which contraceptive method she asked about ("the pill") is contraindicated?
Answer:
Combined hormonal contraceptives (CHCs), which includes most common birth control pills, the patch, and the ring. The CDC assigns this a MEC Category 4 (unacceptable risk) for patients with migraine with aura.
Task 3: What is the clinical reason for this contraindication?
Answer:
The estrogen component of combined hormonal contraceptives independently increases the risk of ischemic stroke. Patients with migraine with aura also have a higher baseline risk of ischemic stroke. The combination of these two risk factors creates an unacceptably high risk for a serious cardiovascular event.
Task 4: Propose two safe and effective contraceptive options to discuss with this patient.
Answer:
Two excellent options are a hormonal IUD (e.g., levonorgestrel IUD) and the progestin-only pill (POP). Both are MEC Category 1 (no restrictions) as they do not contain estrogen. The hormonal IUD offers highly effective, long-acting contraception, while the POP offers a safe daily pill option for patients who prefer that method.
The Scenario: Managing Vasomotor Symptoms in a Complex Patient
A 62-year-old woman presents for a consultation about her severe hot flashes, which have persisted for over 10 years and are worsening. She is interested in menopausal hormone therapy (MHT), but her primary care provider was hesitant due to her age. As the CWHP, you must perform a comprehensive risk/benefit analysis to determine if any MHT options are appropriate and, if not, recommend a safe and effective alternative.
Patient Data & Guidelines
Patient Profile
- Age: 62; 12 years since last menstrual period.
- Uterus Status: Intact.
- Current Meds: Paroxetine 20 mg daily for anxiety.
- PMH: Osteopenia (T-score -1.8).
MHT Guidelines (Excerpt)
- The "Timing Hypothesis": The benefits of systemic MHT are most likely to outweigh the risks for women who are aged <60 or within 10 years of menopause onset.
- For women who initiate MHT more than 10 years from menopause onset or after age 60, the risk of cardiovascular disease and stroke is increased.
- Low-dose paroxetine (7.5 mg) is the only non-hormonal therapy FDA-approved for vasomotor symptoms.
Your Task
Task 1: Based on the "timing hypothesis," is this patient a candidate for initiating standard-dose systemic MHT?
Answer:
No. She is 62 years old (which is >60) and 12 years past her last menstrual period (which is >10 years). She falls outside the "window of opportunity" where the benefits of initiating systemic MHT are most likely to outweigh the risks, particularly the risk of cardiovascular events and stroke.
Task 2: The patient's provider suggests a trial of low-dose oral estrogen. What is the flaw in this recommendation?
Answer:
The recommendation is flawed because it omits a progestogen. The patient has an intact uterus. Administering unopposed estrogen, even at a low dose, would place her at significant risk for endometrial hyperplasia and cancer. Any systemic estrogen therapy must be accompanied by a progestogen in a woman with a uterus.
Task 3: What is a potential drug interaction between her current paroxetine and a common supplement used for menopause?
Answer:
Paroxetine is a potent inhibitor of the CYP2D6 enzyme. Many women use the supplement black cohosh for hot flashes; however, some evidence suggests a link between black cohosh and hepatotoxicity. While not a direct interaction, it is a key counseling point. More directly, if she were to use tamoxifen for breast cancer prevention, paroxetine would significantly inhibit its conversion to its active metabolite, rendering it ineffective.
Task 4: Propose a safe and effective non-hormonal recommendation for her severe vasomotor symptoms.
Answer:
Given that she is already on a standard dose of paroxetine, the best recommendation is to discuss with her provider switching to the specific FDA-approved formulation, paroxetine mesylate 7.5 mg (Brisdelle). While she is already on a higher dose of paroxetine, this dose may not be optimized for vasomotor control. Switching to the specific, lower, FDA-approved dose is an evidence-based first step. If that fails, other non-hormonal options like gabapentin or clonidine could be considered.
The Scenario: Managing Hypertension in Pregnancy
A 32-year-old woman at 10 weeks gestation presents to your pharmacy clinic for a medication review. She has a history of chronic hypertension that was well-controlled on lisinopril prior to her pregnancy. Her obstetrician has advised her to stop the lisinopril and referred her to you for counseling and to recommend a safer alternative. Her blood pressure in the clinic today is 150/95 mmHg.
Patient Data & ACOG Guidelines
Patient Profile
- Age: 32 years old; 10 weeks pregnant.
- Diagnosis: Chronic Hypertension.
- Pre-pregnancy Med: Lisinopril 20mg daily.
- Current BP: 150/95 mmHg.
ACOG Guideline (Excerpt)
- Contraindicated: ACE inhibitors (e.g., lisinopril), ARBs, and direct renin inhibitors are contraindicated in pregnancy due to the risk of fetal renal damage, oligohydramnios, and death.
- First-Line Agents: Labetalol, nifedipine extended-release, and methyldopa are considered first-line agents for the management of chronic hypertension in pregnancy.
- Treatment Goal: Maintain BP < 140/90 mmHg.
Your Task
Task 1: Why is lisinopril absolutely contraindicated in pregnancy?
Answer:
ACE inhibitors like lisinopril carry a boxed warning for use in pregnancy because they are known teratogens. Specifically, use in the second and third trimesters can disrupt the fetal renin-angiotensin system, which is critical for kidney development. This can lead to fetal renal failure, insufficient amniotic fluid (oligohydramnios), lung hypoplasia, and fetal death.
Task 2: What is the primary health risk to both the mother and fetus from her uncontrolled hypertension (150/95 mmHg)?
Answer:
Uncontrolled chronic hypertension significantly increases the risk of developing preeclampsia, a serious pregnancy complication characterized by high blood pressure and organ damage. For the mother, preeclampsia can lead to seizures (eclampsia), stroke, and organ failure. For the fetus, it can lead to poor growth (intrauterine growth restriction) and placental abruption, often necessitating a preterm delivery.
Task 3: Based on the ACOG guidelines, what are two appropriate first-line medication options to recommend?
Answer:
Two appropriate first-line options are labetalol and nifedipine extended-release. Both have extensive safety and efficacy data in pregnancy and are strongly recommended by ACOG. Methyldopa is also a first-line agent but is often less effective and less well-tolerated.
Task 4: Propose a specific starting dose and counseling points for one of your recommended agents.
Answer:
Recommendation: "I recommend starting labetalol at a dose of 100 mg twice daily. This is a standard starting dose."
Counseling Points:
- Safety in Pregnancy: "This medication, labetalol, is considered one of the safest and most effective options for managing blood pressure during pregnancy and will not harm your baby."
- Importance of Control: "It's very important to control your blood pressure to keep both you and the baby healthy and reduce the risk of a serious condition called preeclampsia."
- Monitoring: "We will have you monitor your blood pressure at home and follow up with your OB in 1-2 weeks to see if this dose is working or if we need to adjust it."
